Here’s what you should know:
1. Goldman Sachs cited balance sheet concerns, litigation risks and competition-related pressure as the reason behind the rating.
2. Valeant opened the week at $21.36 Jan. 22, and it was trading at $19.83 as of 1:30 p.m. EST Jan. 24.
3. Valeant hit a 14-month high of $24.45 Jan. 5, but has now dropped below its 10-and 20-day moving averages.
More articles on supply chain:
Congress suspends medical device tax through stopgap spending deal — 6 insights
Cowen: Amazon could leverage Alexa to invade healthcare space
FDA grants IlluminOss marketing clearance for bone stabilization system
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
